SCHEMBL18109239

SCHEMBL18109239

O=S(=O)(Nc1cc[c]cc1)c1cccs1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.62
KMT2A Q03164 5/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
PKM P14618 1/20 0.60
HTT P42858 1/20 0.59
HPGD P15428 4/20 0.56
KDM4E B2RXH2 1/20 0.56
GAA P10253 1/20 0.56
TSHR P16473 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
TP53 P04637 1/20 0.55
LMNA P02545 2/20 0.55
MAPT P10636 2/20 0.55
RORA P35398 1/20 0.55
RORC P51449 1/20 0.55
RORB Q92753 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29031229 0.87 MEN1 (0.77) MEN1KMT2ASMN1; SMN2PKMHTT
SCHEMBL4709087 0.84 MEN1 (0.84) MEN1KMT2ASMN1; SMN2PKMHTT
SCHEMBL15010206 0.82 MEN1 (0.57) MEN1KMT2ASMN1; SMN2PKMHTT
SCHEMBL7569646 0.79 MEN1 (0.71) MEN1KMT2ASMN1; SMN2PKMHTT
SCHEMBL7578748 0.79 MEN1 (0.67) MEN1KMT2ASMN1; SMN2PKMHTT
SCHEMBL10192087 0.79 HTT (0.88) MEN1KMT2ASMN1; SMN2PKMHTT
SCHEMBL12334082 0.79 MEN1 (0.67) MEN1KMT2ASMN1; SMN2PKMHTT
SCHEMBL29118873 0.79 MEN1 (0.71) MEN1KMT2ASMN1; SMN2PKMHTT
SCHEMBL7572267 0.79 PKM (0.68) MEN1KMT2ASMN1; SMN2PKMHTT
SCHEMBL12334083 0.77 MEN1 (1.00) MEN1KMT2ASMN1; SMN2PKMHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113149885-A EBNA1 inhibitors and methods of using the same 威斯塔解剖学和生物学研究所 2021-07-23 CN claimed
US-20180305312-A1 EBNA1 INHIBITORS AND METHODS USING SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-10-25 US claimed
EP-3294705-A1 EBNA1 INHIBITORS AND METHODS USING SAME The Wistar Institute Of Anatomy And Biology (US) 2018-03-21 EP claimed
WO-2016183534-A1 EBNA1 INHIBITORS AND METHODS USING SAME THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2016-11-17 WO claimed
US-11912659-B2 EBNA1 inhibitors and methods using same THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2024-02-27 US disclosed
EP-3068758-B1 EBNA1 INHIBITORS AND THEIR METHOD OF USE WISTAR INST (US) 2021-09-08 EP disclosed
CN-113149885-A EBNA1 inhibitors and methods of using the same 威斯塔解剖学和生物学研究所 2021-07-23 CN disclosed
EP-3294705-B1 EBNA1 INHIBITORS AND METHODS USING SAME WISTAR INST (US) 2021-07-21 EP disclosed
US-10981867-B2 EBNA1 inhibitors and methods using same THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2021-04-20 US disclosed
CN-107848964-B EBNA1 inhibitors and methods of using the same 威斯塔解剖学和生物学研究所 2021-03-19 CN disclosed
US-20200239415-A1 EBNA1 INHIBITORS AND METHODS USING SAME WISTAR INST (US) 2020-07-30 US disclosed
US-10442763-B2 EBNA1 inhibitors and methods using same THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2019-10-15 US disclosed
US-20180305312-A1 EBNA1 INHIBITORS AND METHODS USING SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-10-25 US disclosed
EP-3294705-A1 EBNA1 INHIBITORS AND METHODS USING SAME The Wistar Institute Of Anatomy And Biology (US) 2018-03-21 EP disclosed
US-9856214-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2018-01-02 US disclosed
WO-2016183534-A1 EBNA1 INHIBITORS AND METHODS USING SAME THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2016-11-17 WO disclosed
US-20160289185-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-10-06 US disclosed
CN-103339132-A Novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against raf kinase, containing same as active ingredi YOUAI CO LTD 2013-10-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200239415-A1 EBNA1 INHIBITORS AND METHODS USING SAME MLLT1, EBNA1BP2, MALT1 MEN1 30/4885KMT2A 233/4885SMN1; SMN2 2354/4885
US-20180305312-A1 EBNA1 INHIBITORS AND METHODS USING SAME MLLT1, EBNA1BP2, MALT1 MEN1 30/4885KMT2A 233/4885SMN1; SMN2 2354/4885
US-20160289185-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE MCM5, EBNA1BP2, MLLT1 MEN1 58/4885KMT2A 207/4885SMN1; SMN2 2217/4885
US-10981867-B2 EBNA1 inhibitors and methods using same MLLT1, EBNA1BP2, MALT1 MEN1 30/4885KMT2A 233/4885SMN1; SMN2 2354/4885
US-11912659-B2 EBNA1 inhibitors and methods using same MLLT1, EBNA1BP2, MALT1 MEN1 30/4885KMT2A 233/4885SMN1; SMN2 2354/4885
US-10442763-B2 EBNA1 inhibitors and methods using same MLLT1, EBNA1BP2, MALT1 MEN1 30/4885KMT2A 233/4885SMN1; SMN2 2354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.